A randomized phase III study of single-agent amrubicin Vs. Carboplatin/Etoposide in elderly patients with extensive-disease small-cell lung cancer

导出原文传递

翻译打印收藏纠错

作者： Sekine,I. ^[1] ; Okamoto,H. ^[2] ; Horai,T. ^[3] ; Nakagawa,K. ^[4] ; Ohmatsu,H. ^[5] ; Yokoyama,A. ^[6] ; Katakami,N. ^[7] ; Shibuya,M. ^[8] ; Saijo,N. ; Fukuoka,M.

作者单位： Kinki University School of Medicine, Osakasayama, Japan ^[1] Institute of Biomedical Research and Innovation Hospital, Kobe, Japan ^[2] National Cancer Center Hospital, Tokyo, Japan ^[3] Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan ^[4] Yokohama Municipal Citizens' Hospital, Yokohama, Japan ^[5] Niigata Cancer Center Hospital, Niigata, Japan ^[6] Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan ^[7] National Cancer Center Hospital East, Kashiwa, Japan ^[8]

关键词 Chemotherapy Interstitial lung disease Pulmonary disease Pulmonary toxicity Treatment-related death

发布时间 2014-05-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交